Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company offers biomedical materials, such as collagen and bone materials; beauty care products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, and medical aesthetics, as well as engages in collagen purification activities. It also provides ophthalmic viscoelastic under the PreviscAid, ViscAid, and BiVisc brands; intra-articular injections under the ArtiBest and ArtiAid brands; synthetic bone grafts under the BestAid, GingivAid, FormaGraft, and Foramic brands; and dermal filler injections under the Formaderm brand. In addition, the company offers collagen based regenerative matrixes comprising HealiAid, a collagen wound dressing; NasoAid, an intranasal splint; and FormaAid, a collagen membrane. Maxigen Biotech Inc. was incorporated in 1998 and is headquartered in Taoyuan City, Taiwan.